EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSDLAG00005009191
Gene Symbol: HTR3A
1 Cross references
205 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDLAG00005015560
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSDLAG00005021725
Gene Symbol: ADAM17A
1 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSDLAG00005031926
Gene Symbol: ADAMTS5
1 Cross references
199 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSDLAG00005001823
Gene Symbol: ABCC8
1 Cross references
227 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSDLAG00005007721
Gene Symbol: ATP4B
1 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSDLAG00005006548
Gene Symbol: ATP1A2A
1 Cross references
205 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSDLAG00005026068
Gene Symbol: ATP1B2B
1 Cross references
197 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSDLAG00005032397
Gene Symbol: ATP1B3A
1 Cross references
229 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSDLAG00005003666
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSDLAG00005019426
Gene Symbol: BCL2L10
1 Cross references
129 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSDLAG00005021678
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).